COMPUTATIONAL

核心A项目概述：核心A的主要目标将是支持该计划项目的总体目标，即确定小分子和多肽Env gp120抑制剂，通过利用结构-机制相关性来确定它们的结构作用机制，以此作为优化拮抗剂功能的指导。为此，核心A将结合gpl20单体和Env三聚体的新结构信息，重点介绍该计划项目在开发小分子和模拟多肽的病毒进入拮抗剂方面取得的最新重大进展。我们将重点介绍介导HIV-1感染的三个Env接口。它们是：(A)高度保守的CD4-gp120结合位点；(B)趋化因子受体-gp120 V3环界面；(C)gp20的gp41相互作用元件。在最近的授权期内，Core A成功指导了GP 120拮抗剂的设计、合成和结构确定周期。在这一成功的基础上，我们将继续与结晶学(Hendrickson和Kuong)、病毒学(Sodroski)、多肽和迷你蛋白质(Chaiken)、小分子合成(Smith)、热力学(Freire)和单分子FRET(Moths和Blanchard)相结合。由这些小组发现和验证的拮抗剂(多肽、小分子和片段)将反过来由Core A通过计算进行优化，并与合成(Smith)和多肽/模拟多肽项目(Chaiken)合作，开发用于病毒学测试和验证的新型小分子和多肽(Sodroski)。

Core A Project Summary: The Principal Aim of Core A will be to support the Overarching Goal of this Program Project to identify small molecule and peptide Env gp120 inhibitors, defining their structural mechanisms of action by exploiting structure-mechanism correlations as a guide to optimize antagonist function. To this end, Core A will focus on the recent significant progress made by the Program Project in the development of small molecule and peptidomimetic viral entry antagonists, in conjunction with the emerging structural information of both gpl20 monomer and the Env trimer. We will focus on three Env interfaces that mediate HIV-1 infection. These are: (A) the highly conserved CD4-gp120 binding site; (B) the chemokine receptor-gp120 V3-loop interface; and (C) the gp41-interacfing element of gpl20. During the recent grant period Core A successfully guided cycles of design, synthesis and structure determination for gp 120 antagonists. Building on this success, we will continue to integrate with Crystallography (Hendrickson and Kwong), Virology (Sodroski), Peptide and Mini-proteins (Chaiken), Small Molecule Synthesis (Smith), Thermodynamics (Freire), and Single Molecule FRET (Mothes and Blanchard). Antagonists (peptides, small molecules and fragments) discovered and validated by these groups, will in turn be optimized computationally by Core A, and in collaboration with the Synthetic (Smith) and Peptide/Peptidomimetic Projects (Chaiken) advance novel small molecules and peptides for virological testing and validation (Sodroski).